Article Details

AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 2021-05-10 20:03:45

Tags for this article:

Click the tags to see associated articles and topics

AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update. View article details on hiswai:

Excerpt

Ficlatuzumab is AVEO's potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF). The study was ...

Article found on: financialpost.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up